Avidity Biosciences Inc is a biotechnology company focused on developing innovative therapies that leverage its proprietary AOC platform, which stands for antibody-oligonucleotide conjugates
This platform aims to deliver therapeutic oligonucleotides directly to specific cells using antibodies, thereby enhancing the precision and effectiveness of treatments for various diseases, including genetic disorders and cancer. The company's research is centered around improving the delivery and efficacy of RNA-based therapies, with the goal of transforming the treatment landscape for patients through targeted and personalized medicine.
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular dystrophies.
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in the study's success.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
